-- Transaction to Lock in Ongoing Revenue Stream for Omeros and Focus the Company on its Complement Franchise of MASP-2 and MASP-3 Inhibitors – OMIDRIA will become a key product in Rayner’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results